Measurement properties, feasibility and clinical utility of the Doloplus-2 pain scale in older adults with cognitive impairment: a systematic review

• Published in: BMC geriatrics 2017-11, Vol.17 (1), p.257-257, Article 257
• Main Authors: Rostad, Hanne Marie, Utne, Inger, Grov, Ellen Karine, Puts, Martine, Halvorsrud, Liv
• Format: Article
• Language: English
• Subjects: Cognition disorders; Cognitive ability; Cognitive impairment; Delirium; Dementia; Dementia disorders; Doloplus-2; Evidence-based medicine; Feasibility studies; Geriatrics; Measuring instruments; Older adults; Older people; Pain; Pain management; Patients; Prospero protein; Quality control; Quantitative psychology; Systematic review
• ISSN: 1471-2318; 1471-2318
• DOI: 10.1186/s12877-017-0643-9

The Doloplus-2 is a pain assessment scale for assessing pain in older adults with cognitive impairment. It is used in clinical practice and research. However, evidence for its measurement properties, feasibility and clinical utility remain incomplete. This systematic review synthesizes previous research on the measurement properties, feasibility and clinical utility of the scale. We conducted a systematic search in three databases (CINAHL, Medline and PsycINFO) for studies published in English, French, German, Dutch/Flemish or a Scandinavian language between 1990 and April 2017. We also reviewed the Doloplus-2 homepage and reference lists of included studies to supplement our search. Two reviewers independently reviewed titles and abstracts and performed the quality assessment and data abstraction. A total of 24 studies were included in this systematic review. The quality of the studies varied, but many lacked sufficient detail about the samples and response rates. The Doloplus-2 has been studied using diverse samples in a variety of settings; most study participants were in long-term care and in people with dementia. Sixteen studies addressed various aspects of the scale's feasibility and clinical utility, but their results are limited and inconsistent across settings and samples. Support for the scale's reliability, validity and responsiveness varied widely across the studies. Generally, the reliability coefficients reached acceptable benchmarks, but the evidence for different aspects of the scale's validity and responsiveness was incomplete. Additional high-quality studies are warranted to determine in which populations of older adults with cognitive impairment the Doloplus-2 is reliable, valid and feasible. The ability of the Doloplus-2 to meaningfully quantify pain, measure treatment response and improve patient outcomes also needs further investigation. PROSPERO reg. no.: CRD42016049697 registered 20. Oct. 2016.